Bamco Inc. NY Raises Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Bamco Inc. NY raised its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 48.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,000 shares of the biopharmaceutical company's stock after acquiring an additional 19,500 shares during the quarter. Bamco Inc. NY's holdings in Insmed were worth $4,142,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Tidal Investments LLC increased its holdings in Insmed by 447.0% in the third quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company's stock valued at $1,759,000 after purchasing an additional 19,696 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Insmed by 12.9% during the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock valued at $136,648,000 after purchasing an additional 214,130 shares during the period. Everence Capital Management Inc. bought a new stake in Insmed in the fourth quarter valued at approximately $352,000. Harbor Capital Advisors Inc. raised its holdings in Insmed by 237.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company's stock worth $4,115,000 after purchasing an additional 41,918 shares during the period. Finally, JCIC Asset Management Inc. boosted its position in shares of Insmed by 40.7% during the fourth quarter. JCIC Asset Management Inc. now owns 2,560 shares of the biopharmaceutical company's stock worth $177,000 after purchasing an additional 740 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on INSM. Stifel Nicolaus reduced their target price on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research note on Friday, February 21st. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. UBS Group cut their target price on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research note on Friday. Wells Fargo & Company boosted their price target on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 19th. Finally, JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $93.93.

Insider Buying and Selling at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 37,828 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $78.61, for a total value of $2,973,659.08. Following the completion of the sale, the insider now directly owns 100,165 shares of the company's stock, valued at $7,873,970.65. The trade was a 27.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Roger Adsett sold 42,975 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $78.61, for a total value of $3,378,264.75. Following the transaction, the chief operating officer now directly owns 146,082 shares in the company, valued at $11,483,506.02. This trade represents a 22.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 182,337 shares of company stock worth $14,284,557 over the last three months. 3.00% of the stock is owned by insiders.

Insmed Stock Performance

Shares of Insmed stock traded down $0.55 during trading hours on Friday, reaching $65.08. The company had a trading volume of 2,388,354 shares, compared to its average volume of 2,324,735. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The firm has a market cap of $11.83 billion, a PE ratio of -11.64 and a beta of 0.84. The business has a fifty day simple moving average of $72.61 and a 200 day simple moving average of $73.32.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same quarter in the prior year, the company earned ($1.06) earnings per share. Insmed's revenue was up 22.9% compared to the same quarter last year. On average, analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.